Journal of Clinical Oncology, Vol 15, 2149-2156, Copyright © 1997 by American Society of Clinical Oncology

ARTICLES

Recommended breast cancer surveillance guidelines. American Society of Clinical Oncology

OBJECTIVE: To determine an effective, evidence-based postoperative surveillance strategy for the detection and treatment of recurrent breast cancer. Tests are recommended only if they have an impact on the outcomes specified by the American Society of Clinical Oncology (ASCO) for clinical practice guidelines. POTENTIAL INTERVENTION: All tests described in the literature for postoperative monitoring were considered. In addition, the data were critically evaluated to determine the optimal frequency of monitoring. OUTCOME: Outcomes of interest include overall and disease-free survival, quality of life, toxicity reduction, and secondarily cost-effectiveness. EVIDENCE: A search was performed to determine all relevant articles published over the past 20 years on the efficacy of surveillance testing for breast cancer recurrence. These publications comprised both retrospective and prospective studies. VALUES: Levels of evidence and guideline grades were rated by a standard process. More weight was given to studies that tested a hypothesis that directly related testing to one of the primary outcomes in a randomized design. BENEFITS/HARMS/COSTS: The possible consequences of false-positive and negative tests were considered in evaluating a preference for one of two tests that provided similar information. Cost alone was not a determining factor. RECOMMENDATIONS: The attached guidelines summarize the recommendations of the ASCO breast cancer expert panel (see Table 1 for a summary of guidelines and corresponding levels of evidence and grades of recommendation). Data are sufficient to recommend monthly breast self-examination, annual mammography of the preserved and contralateral breast, and a careful history and physical examination every 3 to 6 months for 3 years, then every 6 to 12 months for 2 years, then annually. Data are not sufficient to recommend routine bone scans, chest radiographs, hematologic blood counts, tumor markers (CEA, CA15-5), liver ultrasonograms, or computed axial tomographic scans. VALIDATION: The recommendations of the breast cancer expert panel were evaluated by the ASCO Health Services Research Committee reviewers and by the ASCO Board of Directors.

This article has been cited by other articles:

				N. L. Keating, M. B. Landrum, E. Guadagnoli, E. P. Winer, and J. Z. Ayanian Surveillance Testing Among Survivors of Early-Stage Breast Cancer J. Clin. Oncol., March 20, 2007; 25(9): 1074 - 1081. [Abstract] [Full Text] [PDF]

				N. L. Keating, M. B. Landrum, E. Guadagnoli, E. P. Winer, and J. Z. Ayanian Factors Related to Underuse of Surveillance Mammography Among Breast Cancer Survivors J. Clin. Oncol., January 1, 2006; 24(1): 85 - 94. [Abstract] [Full Text] [PDF]

				H. T. Williams, S. Smith, and T. Uematsu FDG PET and SPECT of Bone Metastases in Breast Cancer Am. J. Roentgenol., December 1, 2005; 185(6): 1651 - 1653. [Full Text] [PDF]

				N. L. Keating, M. B. Landrum, E. Meara, P. A. Ganz, and E. Guadagnoli Do Increases in the Market Share of Managed Care Influence Quality of Cancer Care in the Fee-For-Service Sector? J Natl Cancer Inst, February 16, 2005; 97(4): 257 - 264. [Abstract] [Full Text] [PDF]

				J.S. Burgers, B. Fervers, M. Haugh, M. Brouwers, G. Browman, T. Philip, and F.A. Cluzeau International Assessment of the Quality of Clinical Practice Guidelines in Oncology Using the Appraisal of Guidelines and Research and Evaluation Instrument J. Clin. Oncol., May 15, 2004; 22(10): 2000 - 2007. [Abstract] [Full Text] [PDF]

				M. Gurevich, G. M. Devins, C. Wilson, D. McCready, C. R. Marmar, and G. M. Rodin Stress Response Syndromes in Women Undergoing Mammography: A Comparison of Women With and Without a History of Breast Cancer Psychosom Med, January 1, 2004; 66(1): 104 - 112. [Abstract] [Full Text] [PDF]

				C. L. Loprinzi, D. Hayes, and T. Smith Doc, Shouldn't We Be Getting Some Tests? J. Clin. Oncol., May 1, 2003; 21(90090): 108s - 111. [Full Text] [PDF]

				M. A. Helvie, J. E. Bailey, M. A. Roubidoux, H. A. Pass, A. E. Chang, L. J. Pierce, and E. G. Wilkins Mammographic Screening of TRAM Flap Breast Reconstructions for Detection of Nonpalpable Recurrent Cancer Radiology, July 1, 2002; 224(1): 211 - 216. [Abstract] [Full Text]

				B. Bernhardt, D. Hayes, C. L. Loprinzi, and T. J. Smith Correspondence Re: ""Doc, Shouldn't We Be Getting Some Tests?"" J. Clin. Oncol., November 1, 2000; 18(21): 3739 - 3741. [Full Text] [PDF]

				H. J. Burstein and E. P. Winer Primary Care for Survivors of Breast Cancer N. Engl. J. Med., October 12, 2000; 343(15): 1086 - 1094. [Full Text] [PDF]

				C. L. Loprinzi, D. Hayes, and T. Smith Doc, Shouldn't We Be Getting Some Tests? J. Clin. Oncol., June 11, 2000; 18(11): 2345 - 2348. [Full Text] [PDF]

				A. C. Wolff and N. E. Davidson Primary Systemic Therapy in Operable Breast Cancer J. Clin. Oncol., April 7, 2000; 18(7): 1558 - 1569. [Abstract] [Full Text] [PDF]

				D. Mille, T. Roy, M.-O. Carrere, I. Ray, N. Ferdjaoui, H.-M. Spath, F. Chauvin, and T. Philip Economic Impact of Harmonizing Medical Practices: Compliance With Clinical Practice Guidelines in the Follow-Up of Breast Cancer in a French Comprehensive Cancer Center J. Clin. Oncol., April 1, 2000; 18(8): 1718 - 1724. [Abstract] [Full Text] [PDF]

				R. T. Penson, M. V. Seiden, K. M. Shannon, M. L. Lubratovich, M. Roche, B. A. Chabner, and T. J. Lynch Jr. Communicating Genetic Risk: Pros, Cons, and Counsel Oncologist, April 1, 2000; 5(2): 152 - 161. [Abstract] [Full Text]

				T. J. Smith, N. E. Davidson, D. V. Schapira, E. Grunfeld, H. B. Muss, V. G. Vogel III, and M. R. Somerfield American Society of Clinical Oncology 1998 Update of Recommended Breast Cancer Surveillance Guidelines J. Clin. Oncol., March 1, 1999; 17(3): 1080 - 1080. [Abstract] [Full Text] [PDF]

				G. N. Hortobagyi Treatment of Breast Cancer N. Engl. J. Med., October 1, 1998; 339(14): 974 - 984. [Full Text] [PDF]

				Integrating Economic Analysis Into Cancer Clinical Trials: the National Cancer Institute-American Society of Clinical Oncology Economics Workbook J Natl Cancer Inst Monographs, August 1, 1998; 1998(24): 1 - 28. [Full Text]